These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 23084330)

  • 1. Combination of diffusion-weighted magnetic resonance imaging and extended prostate biopsy predicts lobes without significant cancer: application in patient selection for hemiablative focal therapy.
    Matsuoka Y; Numao N; Saito K; Tanaka H; Kumagai J; Yoshida S; Koga F; Masuda H; Kawakami S; Fujii Y; Kihara K
    Eur Urol; 2014 Jan; 65(1):186-92. PubMed ID: 23084330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Candidate selection for quadrant-based focal ablation through a combination of diffusion-weighted magnetic resonance imaging and prostate biopsy.
    Matsuoka Y; Numao N; Saito K; Tanaka H; Kumagai J; Yoshida S; Ishioka J; Koga F; Masuda H; Kawakami S; Fujii Y; Kihara K
    BJU Int; 2016 Jan; 117(1):94-101. PubMed ID: 25124332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient selection for hemiablative focal therapy of prostate cancer: variables predictive of tumor unilaterality based upon radical prostatectomy.
    Polascik TJ; Mayes JM; Schroeck FR; Sun L; Madden JF; Moul JW; Mouraviev V
    Cancer; 2009 May; 115(10):2104-10. PubMed ID: 19288576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diffusion-weighted magnetic resonance imaging in patients with unilateral prostate cancer on extended prostate biopsy: predictive accuracy of laterality and implications for hemi-ablative therapy.
    Jeong IG; Kim JK; Cho KS; You D; Song C; Hong JH; Ahn H; Kim CS
    J Urol; 2010 Nov; 184(5):1963-9. PubMed ID: 20851437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of multiparametric MRI and transperineal template-guided mapping biopsy of the prostate to identify candidates for hemi-ablative focal therapy.
    Tran M; Thompson J; Böhm M; Pulbrook M; Moses D; Shnier R; Brenner P; Delprado W; Haynes AM; Savdie R; Stricker PD
    BJU Int; 2016 Jan; 117(1):48-54. PubMed ID: 25682968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discrepancy in prostate cancer localization between biopsy and prostatectomy specimens in patients with unilateral positive biopsy: implications for focal therapy.
    Sinnott M; Falzarano SM; Hernandez AV; Jones JS; Klein EA; Zhou M; Magi-Galluzzi C
    Prostate; 2012 Aug; 72(11):1179-86. PubMed ID: 22161896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of clinical characteristics and transrectal ultrasound-guided biopsy to predict lobes without significant cancer: application in patient selection for hemiablative focal therapy.
    Jung JW; Lee BK; Choi WS; Park YH; Lee S; Jeong SJ; Lee SE; Byun SS
    Prostate Int; 2014 Mar; 2(1):37-42. PubMed ID: 24693533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate cancer: role of pretreatment multiparametric 3-T MRI in predicting biochemical recurrence after radical prostatectomy.
    Park JJ; Kim CK; Park SY; Park BK; Lee HM; Cho SW
    AJR Am J Roentgenol; 2014 May; 202(5):W459-65. PubMed ID: 24758681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can conventional magnetic resonance imaging, prostate needle biopsy, or their combination predict the laterality of clinically localized prostate cancer?
    Jeong CW; Ku JH; Moon KC; Hong SK; Byun SS; Cho JY; Kim HH; Kim SH; Lee SE; Kwak C
    Urology; 2012 Jun; 79(6):1322-7. PubMed ID: 22656409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ability of preoperative 3.0-Tesla magnetic resonance imaging to predict the absence of side-specific extracapsular extension of prostate cancer.
    Hara T; Nakanishi H; Nakagawa T; Komiyama M; Kawahara T; Manabe T; Miyake M; Arai E; Kanai Y; Fujimoto H
    Int J Urol; 2013 Oct; 20(10):993-9. PubMed ID: 23360237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unilateral positive biopsies in low risk prostate cancer patients diagnosed with extended transrectal ultrasound-guided biopsy schemes do not predict unilateral prostate cancer at radical prostatectomy.
    Gallina A; Maccagnano C; Suardi N; Capitanio U; Abdollah F; Raber M; Salonia A; Scattoni V; Rigatti P; Montorsi F; Briganti A
    BJU Int; 2012 Jul; 110(2 Pt 2):E64-8. PubMed ID: 22093108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The predictive value of endorectal 3 Tesla multiparametric magnetic resonance imaging for extraprostatic extension in patients with low, intermediate and high risk prostate cancer.
    Somford DM; Hamoen EH; Fütterer JJ; van Basten JP; Hulsbergen-van de Kaa CA; Vreuls W; van Oort IM; Vergunst H; Kiemeney LA; Barentsz JO; Witjes JA
    J Urol; 2013 Nov; 190(5):1728-34. PubMed ID: 23680307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of transrectal saturation biopsy in tumour localization: pathological correlation after retropubic radical prostatectomy and implication for focal ablative therapy.
    Abdollah F; Scattoni V; Raber M; Roscigno M; Briganti A; Suardi N; Gallina A; Capitanio U; Freschi M; Salonia A; Cestari A; Guazzoni G; Rigatti P; Montorsi F
    BJU Int; 2011 Aug; 108(3):366-71. PubMed ID: 21087451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Usefulness of prebiopsy multifunctional and morphologic MRI combined with free-to-total prostate-specific antigen ratio in the detection of prostate cancer.
    Vilanova JC; Barceló-Vidal C; Comet J; Boada M; Barceló J; Ferrer J; Albanell J
    AJR Am J Roentgenol; 2011 Jun; 196(6):W715-22. PubMed ID: 21606259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incremental value of T2-weighted and diffusion-weighted MRI for prediction of biochemical recurrence after radical prostatectomy in clinically localized prostate cancer.
    Nishida K; Yuen S; Kamoi K; Yamada K; Akazawa K; Ito H; Okihara K; Kawauchi A; Miki T; Nishimura T
    Acta Radiol; 2011 Feb; 52(1):120-6. PubMed ID: 21498337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High diagnostic ability of multiparametric magnetic resonance imaging to detect anterior prostate cancer missed by transrectal 12-core biopsy.
    Komai Y; Numao N; Yoshida S; Matsuoka Y; Nakanishi Y; Ishii C; Koga F; Saito K; Masuda H; Fujii Y; Kawakami S; Kihara K
    J Urol; 2013 Sep; 190(3):867-73. PubMed ID: 23542406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Magnetic resonance imaging‑directed biopsy improves the prediction of prostate cancer aggressiveness compared with a 12‑core transrectal ultrasound‑guided prostate biopsy.
    Zhang J; Xiu J; Dong Y; Wang M; Han X; Qin Y; Huang Z; Cai S; Yuan X; Liu Q
    Mol Med Rep; 2014 May; 9(5):1989-97. PubMed ID: 24584266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of multiparametric magnetic resonance imaging and transrectal ultrasound-guided prostate biopsies is not enough for identifying patients eligible for hemiablative focal therapy for prostate cancer.
    Choi YH; Yu JW; Kang MY; Sung HH; Jeong BC; Seo SI; Jeon SS; Lee HM; Jeon HG
    World J Urol; 2019 Oct; 37(10):2129-2135. PubMed ID: 30603783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does suspicion of prostate cancer on integrated T2 and diffusion-weighted MRI predict more adverse pathology on radical prostatectomy?
    Borofsky MS; Rosenkrantz AB; Abraham N; Jain R; Taneja SS
    Urology; 2013 Jun; 81(6):1279-83. PubMed ID: 23394882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate cancer detection: comparison of T2-weighted imaging, diffusion-weighted imaging, proton magnetic resonance spectroscopic imaging, and the three techniques combined.
    Chen M; Dang HD; Wang JY; Zhou C; Li SY; Wang WC; Zhao WF; Yang ZH; Zhong CY; Li GZ
    Acta Radiol; 2008 Jun; 49(5):602-10. PubMed ID: 18568549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.